Why Theriva Biologics Shares Are Booming Today
Portfolio Pulse from Adam Eckert
Theriva Biologics Inc's shares are trading higher after the FDA granted orphan drug designation to VCN-01, the company's systemic, selective, stroma-degrading oncolytic adenovirus for the treatment of pancreatic cancer. The drug is being evaluated in combination with standard-of-care chemotherapy as a first line therapy for patients with pancreatic ductal adenocarcinoma. The FDA had previously granted orphan drug designation to VCN-01 for the treatment of retinoblastoma.
June 28, 2023 | 1:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theriva Biologics' shares are trading higher after the FDA granted orphan drug designation to its pancreatic cancer treatment, VCN-01. This positive regulatory development could boost investor confidence in the company's pipeline.
The FDA's orphan drug designation for Theriva's VCN-01 is a significant regulatory milestone that validates the drug's potential for treating pancreatic cancer. This could increase investor confidence in Theriva's pipeline, potentially driving the company's stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100